Trending Aesthetic Treatments: What Patients Are Asking For

The neck and chest have moved from afterthought to primary concern. Allergan Aesthetics received FDA approval for Skinvive by Juvéderm (hyaluronic acid injectable gel) specifically for neck wrinkles and appearance improvement, signaling manufacturer recognition that this zone drives patient inquiries. Neck skin is thinner, moves constantly, and shows age dramatically—patients notice it, and social media amplifies the visibility. Practices are packaging neck treatments into existing facelift and lower-face consultations, often bundling Skinvive with neuromodulator units or traditional fillers. The economics: Skinvive is a syringe-based product with per-syringe cost and reimbursement similar to other Juvéderm offerings; practices should model 1–2 syringes per neck patient. Demand is real and growing; practices without a neck protocol are losing consultations to those offering it.

Radiofrequency skin tightening—specifically monopolar RF—is experiencing accelerated adoption. Cynosure Lutronic's XERF (next-generation monopolar RF) is expanding globally with adoption rates climbing; practices are reporting strong patient interest in non-invasive alternatives to surgical tightening. The appeal: no downtime, no incisions, results visible over weeks to months. Monopolar RF penetrates deeper than fractional laser or microneedling, making it effective for laxity on the face, neck, and body. Acquisition cost is significant (device leasing or purchase typically $80K–$150K+ depending on platform), but per-treatment margins are strong once volume reaches 8–12 treatments per week. Patient perception of RF as "non-invasive facelift" is driving demand, particularly among 45–65-year-olds. Practices should evaluate RF as a volume play: it requires training, consistent patient education, and realistic expectation-setting, but the recurring revenue is reliable.

Filler demand is shifting toward biostimulators and dynamic volumizers that trigger collagen remodeling rather than passive fill. Restylane Contour (Galderma) recently gained FDA approval for temple hollowing, expanding the anatomic zones where practitioners can position volumizers as structural solutions. RHA Dynamic Volume (Revance) is cleared for midface augmentation and age-related volume loss, offering rheological properties designed to move naturally with facial expression. These products command premium pricing (typically $100–$150 per syringe wholesale vs. $60–$90 for traditional HA fillers) and require patient education on mechanism and timeline. Demand is driven by the "natural results" narrative and the clinical reality that biostimulators address underlying collagen loss, not just surface wrinkles. Practices should audit their filler mix: if you're still positioning all fillers as temporary smoothing agents, you're leaving margin and patient satisfaction on the table. Biostimulators require longer patient intervals (often 3–4 weeks between treatments) but higher per-syringe revenue.

The neuromodulator market is fragmenting. Relabotulinumtoxin A (Galderma's competitor to Botox and Dysport) is under FDA regulatory review, and Evolus continues to market Jeuveau as a lower-cost alternative. Medicare price negotiation now includes Botox, creating downward pressure on reimbursement and private-pay pricing. Practices relying on neuromodulator volume for margin are facing compression. The strategic response: bundle neuromodulators with higher-margin treatments (RF, biostimulators, injectables), position them as maintenance therapy rather than standalone, and evaluate loyalty programs (Alle, Aspire, Evolus Rewards) to optimize rebates and patient retention. Practices should also monitor Relabotulinumtoxin A approval timing; if approved, competitive pricing will intensify. The trend is clear: neuromodulator-only practices will struggle; practices offering integrated treatment plans will capture more patient lifetime value.

Steel Partners has made an unsolicited acquisition proposal for InMode (a major RF and energy-device manufacturer), signaling consolidation in the device space. L'Oreal is increasing its stake in Galderma to 20%, reinforcing the trend of luxury conglomerates acquiring aesthetic-device and injectables companies. Consolidation typically leads to price increases, supply-chain rationalization, and shifts in rebate programs. Practices should: (1) lock in device leases or purchase agreements before major consolidations close; (2) diversify equipment suppliers to avoid single-vendor dependency; (3) monitor manufacturer loyalty programs for changes in rebate structure post-acquisition. Consolidation also creates opportunity—acquired companies often rationalize product lines, sometimes discounting legacy equipment. Practices should engage with their device reps now to understand post-acquisition roadmaps and negotiate favorable terms before new ownership takes control.

Before adding a trending treatment, apply this checklist: Demand validation: Survey your existing patient base and track incoming inquiries by treatment type for 30 days. If fewer than 2–3 patients per week ask for it unprompted, demand may be overstated. Margin math: Calculate per-unit or per-treatment cost (product + staff time + overhead allocation), realistic per-unit revenue, and break-even patient volume. For devices, include leasing or amortized purchase cost. Training and credentialing: Confirm your staff can be trained and credentialed efficiently; some treatments require manufacturer certification or additional licensing. Competitive landscape: Map which competitors in your market offer it; if saturation is high, differentiation is harder. Patient lifetime value: Prioritize treatments that drive repeat visits and cross-selling (e.g., RF tightening often leads to filler and neuromodulator consultations). Avoid one-off treatments with low repeat rates. Inventory and cash flow: Ensure you can stock product without excessive carrying cost or waste. Align ordering with patient volume projections, not manufacturer incentives.